https://scholars.lib.ntu.edu.tw/handle/123456789/584466
標題: | Association Between Pioglitazone Use and Prostate Cancer: A Population-Based Case-Control Study in the Han Population | 作者: | Kao L.-T. Xirasagar S. Lin H.-C. CHAO-YUAN HUANG |
關鍵字: | pioglitazone; prostate cancer; thiazolidinedione | 公開日期: | 2019 | 出版社: | Blackwell Publishing Inc. | 卷: | 59 | 期: | 3 | 起(迄)頁: | 344-349 | 來源出版物: | Journal of Clinical Pharmacology | 摘要: | To date, few epidemiologic studies have investigated the relationship between pioglitazone use and prostate cancer. The available studies show conflicting findings. This case-control study explored the association between prior pioglitazone usage and prostate cancer using a large, population-based data set. Data were derived from the Longitudinal Health Insurance Database 2005 in Taiwan, a population-based sample of National Health Insurance enrollees with longitudinal claims data since 1995. Cases were 3513 patients with prostate cancer aged over 40?years, and the controls were 3513 patients without prostate cancer, matched with prostate cancer cases on age, and having a medical care utilization episode in the year of the index prostate cancer (1 control per case). We performed conditional logistic regression to examine the odds ratio and 95% confidence intervals for prior pioglitazone use between cases and controls. Analysis showed that 178 of the total sample patients (2.53%) had used pioglitazone prior to the index date. Prior pioglitazone use was found in 72 (2.05%) cases and 106 (3.02%) controls. The crude odds ratio of prior pioglitazone usage for cases was 0.67 (95% confidence interval, 0.50-0.91) compared to controls. After adjusting for demographic characteristics and comorbidities, the negative association of prior pioglitazone with prostate cancer persisted (adjusted odds ratio, 0.59; 95% confidence interval, 0.43-0.80). We concluded that there was an inverse association between prior pioglitazone usage and prostate cancer in this study. ? 2018, The American College of Clinical Pharmacology |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055159405&doi=10.1002%2fjcph.1326&partnerID=40&md5=d3119e2f3fe6b7353e742b4c289ec109 https://scholars.lib.ntu.edu.tw/handle/123456789/584466 |
ISSN: | 0091-2700 | DOI: | 10.1002/jcph.1326 | SDG/關鍵字: | pioglitazone; antidiabetic agent; pioglitazone; adult; aged; cancer control; case control study; comorbidity; controlled study; disease association; drug use; Han Chinese; health care utilization; human; longitudinal study; major clinical study; male; middle aged; national health insurance; population based case control study; prostate cancer; very elderly; non insulin dependent diabetes mellitus; prostate tumor; Taiwan; Adult; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Prostatic Neoplasms; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。